Rabies Immunoglobulins (RIG) are an essential part of optimal management of rabies exposures [World Health Organization (WHO)]. They provide protection against the virus during the critical initial 7 days before adequate endogenous vaccine induced antibodies are formed. Even though Human Rabies Immune Globulin (HRIG) is the ideal product for post-exposure rabies treatment it, like most biological, can cause very rare adverse reactions. A retrospective review of a series of 8737 patients, who received HRIG at one institution, revealed that only 15 (0.183 %) reported transient mild adverse reactions.